The ARL6IP1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This polyclonal knockout model is engineered for the loss-of-function study of ARL6IP1, a gene encoding an endoplasmic reticulum (ER)-shaping protein implicated in ER morphology maintenance, protein trafficking, and apoptosis regulation. The product provides a heterogeneous pool of edited cells, enabling robust functional analyses in a cancer-relevant background without the constraints of single-cell clonal selection. Researchers can employ this population to dissect ARL6IP1-dependent signaling networks and stress responses, leveraging the model’s genetic diversity to capture population-level phenotypes.
The host A-549 cell line was originally established from the lung adenocarcinoma of a 58-year-old Caucasian male and has since become a widely utilized model for alveolar type II epithelium and non-small-cell lung cancer research. A-549 cells retain key features of epithelial origin, including the expression of surfactant proteins and the capacity to undergo epithelial-mesenchymal transition. Their genetic background, harboring KRAS and STK11 mutations, renders them particularly relevant for investigating oncogenic signaling, metabolic reprogramming, and therapeutic resistance mechanisms. In the context of ARL6IP1 disruption, the A-549 platform enables the examination of ER homeostasis and cell death pathways in a lung adenocarcinoma milieu, facilitating translational insights into cancer biology.
ARL6IP1 functions as an ER morphogenic factor that interacts with reticulon family proteins and atlastins to shape the tubular ER network. It is positioned at the intersection of multiple stress-responsive pathways, acting downstream of ER stress sensors such as ATF6, IRE1, and PERK, and upstream of downstream targets including REEP proteins and LC3, a marker of autophagy. ARL6IP1 also interacts with Bcl-2 family members, including BCL-2 and BAX, integrating apoptotic signals at the ER membrane. Its knockout is predicted to induce chronic ER stress, as evidenced by activation of the unfolded protein response (UPR) effectors BiP and CHOP, impair autophagy flux, and heighten apoptotic sensitivity. These perturbations may be mediated through disrupted interactions with the core machinery of ER network dynamics and mitochondrial apoptosis regulation.
In the A-549 lung adenocarcinoma context, ARL6IP1 knockout provides a clinically significant model to investigate the crosstalk between oncogenic stress, ER homeostasis, and programmed cell death. Lung cancer cells frequently encounter microenvironmental stressors that challenge protein-folding capacity and redox balance; thus, ARL6IP1 loss-of-function may shed light on adaptive mechanisms or vulnerabilities exploitable for therapeutic intervention. Moreover, this model offers a platform to study the molecular underpinnings of hereditary spastic paraplegia type SPG61, a neurodegenerative disorder linked to ARL6IP1 mutations, by examining gain-of-toxicity phenotypes in a neuronal context. Simultaneously, the polyclonal nature permits the study of heterogeneous responses to ER stress-inducing chemotherapeutics, such as tunicamycin or proteasome inhibitors, closely mimicking the diverse clonal evolution observed in tumors.
This product is extensively applicable in assays such as Western blotting, RT-qPCR, immunofluorescence, and flow cytometry to validate ARL6IP1 disruption and downstream pathway alterations. Functional studies can include Annexin V-based apoptosis assays, tunicamycin-induced ER stress challenge experiments, and drug sensitivity screenings to assess chemoresistance. Researchers may further employ migration and invasion assays to explore the gene??s role in metastatic behavior. By combining these techniques, users can dissect the interplay between ARL6IP1, ER stress, autophagy, and apoptosis in lung adenocarcinoma. For comprehensive technical support and ordering details, please contact Ascent Research.
